Virtual care companies rush to ease access to Covid-19 antivirals
As two new antiviral pills for Covid-19 approach emergency authorization, experts are concerned that a lack of public health infrastructure — especially easy access to fast-turnaround testing and quickly filled prescriptions — will prevent them from making a meaningful dent in the pandemic.
“We know that these antivirals are going to have a window of opportunity where their effectiveness is optimal, and it can be difficult to get an appointment and get a prescription,” said infectious disease specialist Amesh Adalja, a senior scholar at the Johns Hopkins Center for Health Security.
Read Original Article: Virtual care companies rush to ease access to Covid-19 antivirals »
